Terns' oral weight-loss drug shows promise in early study, shares jump
Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early-stage study, joining drugmakers vying for a share of the lucrative weight-loss treatment market and sending its shares up 27% on Monday.
Terns Pharmaceuticals shares rose 27% after early trials of their obesity drug showed significant weight loss.
FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...
Terns intends to use the net proceeds from the proposed offering to fund research, clinical trials, development and manufacturing of the Company’s key product candidates, including TERN-701, TERN-601 ...
6d
Our data suggests that insiders own under 1% of Terns Pharmaceuticals, Inc. in their own names. It appears that the board ...
Terns Pharmaceuticals unveiled early-phase weight loss data from an oral GLP-1 agonist that it says could be more tolerable ...
Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results ...
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback